Evidence map›Paper›PMID 22542873›Full record

ArticleNeuroscience2012

Activation of alpha1-adrenoceptors enhances glutamate release onto ventral tegmental area dopamine cells.

M C Velásquez-Martinez, R Vázquez-Torres, C A Jiménez-Rivera

Abstract read
In one paragraph

Article in Neuroscience, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.4field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. AlphaFrontiers in behavioral neuroscience · 2022
    Article
  9. Review
  10. Article
  11. Current Developments on the Role of αFrontiers in cell and developmental biology · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. αFrontiers in pharmacology · 2020
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

M C Velásquez-MartinezDepartment of Physiology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico, USA.
R Vázquez-Torres
C A Jiménez-Rivera
University of Puerto Rico, Medical Sciences Campus · PR

Funding

UPR--MEDICAL SCIENCES CAMPUS, MBRS PROGRAMS06GM008224 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SILVA, WALTER I · 1989 to 2008
$28.0M
PKMzeta involvement in cocaine sensitizationSC1GM084854 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI JIMENEZ-RIVERA, CARLOS A · 2008 to 2016
$2.4M
NIGMS NIH HHS GM-08224NIGMS NIH HHS S06 GM008224NIGMS NIH HHS SC1 GM084854
6 · The paper itself

Abstract

The ventral tegmental area (VTA) plays an important role in reward and motivational processes that facilitate the development of drug addiction. Glutamatergic inputs into the VTA contribute to dopamine (DA) neuronal activation related to reward and response-initiating effects in drug abuse. Previous investigations indicate that alpha1-adrenoreceptors (α1-ARs) are primarily localized at presynaptic elements in the ventral midbrain. Studies from several brain regions have shown that presynaptic α1-AR activation enhances glutamate release. Therefore, we hypothesized that glutamate released onto VTA-DA neurons is modulated by pre-synaptic α1-AR. Recordings were obtained from putative VTA-DA cells of male Sprague-Dawley rats (28-50 days postnatal) using voltage clamp techniques. Phenylephrine (10 μM) and methoxamine (80μM), both α1-AR agonists, increased AMPA receptor-mediated excitatory postsynaptic currents' (EPSCs) amplitude evoked by electrical stimulation of afferent fibers (p<0.05). This effect was blocked by the α1-AR antagonist prazosin (1 μM). Phenylephrine decreased the paired-pulse ratio (PPR) and increased spontaneous EPSCs' frequencies but not their amplitudes suggesting a presynaptic locus of action. No changes in miniature EPSCs (0.5μM, tetrodotoxin [TTX]) were observed after phenylephrine's application which suggests that α1-AR effect was action potential dependent. Normal extra- and intracellular Ca(2+) concentration seems necessary for the α1-AR effect since phenylephrine in low Ca(2+) artificial cerebrospinal fluid (ACSF) and depletion of intracellular Ca(2+) stores with thapsigargin (10 μM) failed to increase the AMPA EPSCs' amplitude. Chelerythrine (1μM, protein kinase C (PKC) inhibitor) but not Rp-cAMPS (11 μM, PKA inhibitor) blocked the α1-AR activation effect on AMPA EPSCs, indicating that a PKC intracellular pathway is required. These results demonstrated that presynaptic α1-AR activation modulates glutamatergic inputs that affect VTA-DA neuronal excitability. α1-AR action might be heterosynaptically localized at glutamatergic fibers terminating onto VTA-DA neurons. It is suggested that drug-induced changes in α1-AR could be part of the neuroadaptations occurring in the mesocorticolimbic circuitry during the addiction process.

Indexed as

Action PotentialsAdrenergic alpha-1 Receptor AgonistsAdrenergic alpha-1 Receptor AntagonistsAnimalsDopaminergic NeuronsExcitatory Postsynaptic PotentialsGlutamic AcidMaleNeuronsRatsRats, Sprague-DawleyReceptors, Adrenergic, alpha-1Receptors, AMPAReceptors, Dopamine D1Signal TransductionSynaptic TransmissionAdrenergic alpha-1 Receptor AgonistsAdrenergic alpha-1 Receptor AntagonistsGlutamic AcidReceptors, Adrenergic, alpha-1Receptors, AMPAReceptors, Dopamine D1

Identifiers

PMID22542873
PMCPMC3809080
OpenAlexW1999758827

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.